Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression|
|Citation:||Australian and New Zealand Journal of Psychiatry, 2008; 42(4):346-349|
|Publisher:||Blackwell Publishing Asia|
|Gin S. Malhi, Felicity Ng and Michael Berk|
|Abstract:||Objective: Venlafaxine and mirtazapine in combination are increasingly used in clinical practice to treat treatment-refractory depression. Putative efficacy for this combination of antidepressants, beyond that of monotherapy, stems from their synergistic actions. This paper describes a prospective case series that examined the efficacy of the venlafaxine–mirtazapine combination in the treatment of depressed patients who had failed at least one antidepressant trial. Method: Twenty-two depressed patients with major depression were treated with venlafaxine and mirtazapine in combination for an average of just under 8weeks. Baseline ratings on the 17-item Hamilton Depression Rating Scale (HAM-D17), Montgomery–Åsberg Depression Rating Scale (MADRS) and the Clinical Global Impression–Severity Scale (CGI-S) were repeated at end-point, determined by the naturalistic termination of the depressive treatment episode or the discontinuation of the combination treatment due to adverse effects. The length of treatment until end-point was documented for each patient. Descriptive statistics were used on the collated data. Results: At baseline, mean scores were 28.8 (SD=3.8) for HAM-D17, 30.1 (SD=5.8) for MADRS, and 4.5 (SD=0.5) for CGI-S, reflecting a cohort at the moderate to severe end of the spectrum. At end-point, mean absolute scores were 10.2 (SD=4.7) for HAM-D17, 10.8 (SD=4.6) for MADRS, and 2.3 (SD=0.6) for CGI-S. Mean change from baseline was 18.6 (SD=6.4) for HAM-D17, 19.3 (SD=6.8) for MADRS, and 2.3 (SD=0.6) for CGI-S. Mean duration of treatment was approximately 8weeks, producing a response rate of 81.8% and a remission rate of 27.3%. Only one patient was unable to tolerate the combination although nearly half (10) had significant side-effects during treatment. Conclusion: This study demonstrates relatively high response and remission rates that are encouraging and contribute to the efficacy database for this antidepressant combination. Further studies using randomized controlled designs are needed.|
Antidepressive Agents, Second-Generation
Antidepressive Agents, Tricyclic
Drug Therapy, Combination
Severity of Illness Index
Psychiatric Status Rating Scales
|Appears in Collections:||Aurora harvest 5|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.